págs. 685-693
págs. 695-718
Role of sonic hedgehog signaling pathway in the regulation of ion channels: focus on its association with cardio-cerebrovascular diseases
págs. 719-730
Álbert S. Peixoto, Mayara F. Moreno, Érique Castro, Luiz A. Perandini, Thiago Belchior, Tiago E. Oliveira, Thayna S. Vieira, Gustavo R. Gilio, Caroline A. Tomazelli, Bianca F. Leonardi, Milene Ortiz Silva, Luciano P. Silva Junior, Eduardo H. Moretti, Alexandre A. Steiner, William T. Festuccia
págs. 731-743
Gut microbiota might mediate the benefits of high-fiber/acetate diet to cardiac hypertrophy mice
Meifang Chen, Liming Peng, Chenglong Zhang, Qiong Liu, Tianyi Long, Qiying Xie
págs. 745-756
Rab11-FIP4 interacts with ARF5 to promote cancer stemness in hepatocellular carcinoma
Feifeng Song, Qi Zhang, Xixuan Lu, Tong Xu, Qing Hu, Xiaoping Hu, Weijiao Fan, Yiwen Zhang, Ping Huang
págs. 757-770
págs. 771-785
Endothelial NOX5 overexpression induces changes in the cardiac gene profile: potential impact in myocardial infarction?
Adriana Cortés Jiménez, Javier Marqués Cantero, Álvaro Pejenaute, Elena Ainzúa Pérez, Eduardo Ansorena Artieda, Gloria Abizanda, Felipe Prósper Cardoso, Carlos de Miguel, Guillermo Zalba Goñi
págs. 787-797
Binge drinking leads to an oxidative and metabolic imbalance in skeletal muscle during adolescence in rats: endocrine repercussion
Inés Romero Herrera, Fátima Nogales Bueno, Javier Díaz Castro, Jorge Moreno Fernandez, Maria Del Carmen Gallego López, Julio José Ochoa Herrera, Olimpia Carreras Sánchez, María Luisa Ojeda Murillo
págs. 799-810
Frontiers in fatty liver: recent advances in pathogenic mechanisms, assessment of patients’ prognosis and pharmacotherapy: MASLD: new pathogenic mechanisms, risk assessment tools and drug therapies
Maite García Fernández de Barrena, Matias Antonio Ávila Zaragozá
págs. 811-813
págs. 815-831
Carlota Tuero, Sara Becerril Mañas, Silvia Ezquerro Ezquerro, Gabriela Neira, Gema Frühbeck Martínez, Amaia Rodríguez
págs. 833-849
Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers
Francesca Terracciani, Andrea Falcomatà, Paolo Gallo, Antonio Picardi, Umberto Vespasiani Gentilucci
págs. 851-868
Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment
Paloma Sangro del Alcázar, Manuel Antonio de la Torre Aláez, Bruno Sangro Gómez Acebo, Delia D'Avola
págs. 869-879
Antifibrogenic and apoptotic effects of Ocoxin in cultured rat hepatic stellate cells
Marina Ruiz de Galarreta Martinez, Elena Arriazu Ruiz, María del Pilar Pérez de Obanos Martell, Eduardo Ansorena Artieda, María Jose Iraburu Elizalde
págs. 881-890
págs. 891-899
Comprehensive analysis of epigenetic and epitranscriptomic genes’ expression in human NAFLD
Jose M. Herranz, Amaya López Pascual, Alex Clavería Cabello, Iker Uriarte Diaz Varela, María Ujué Latasa, Ainara Irigaray Miramon, Elena Adán Villaescusa, Borja Castelló Uribe, Bruno Sangro Gómez Acebo, María Arechederra, Maria del Carmen Berasain Lasarte, Matias Antonio Ávila Zaragozá, Maite García Fernández de Barrena
págs. 901-924
© 2001-2024 Fundación Dialnet · Todos los derechos reservados